 |
|
Direct-acting antivirals response in hepatocellular carcinoma: Does the presence of hepatocellular carcinoma matter?
Chung-Feng Huang, Ming-Lung Yu
Clin Mol Hepatol. 2019;25(2):168-171. Published online 2019 Feb 11 DOI: https://doi.org/10.3350/cmh.2018.1014
|
|
Citations to this article as recorded by
 Achieving SVR in patients with hepatitis C-related HCC is associated with an improvement in overall survival: real word data
María Fernanda Guerra Veloz, Sital Shah, James Lok, Almuthana Mohamed, Mary Cannon, Paul J Ross, Ivana Carey, Kosh Agarwal
Hepatoma Research.2024;[Epub] CrossRef Comparison of the efficacy and safety of direct-acting antiviral therapy with or without hepatitis C-related hepatocellular carcinoma
Byung Soo Kwan, Jeong Han Kim, Seong Jun Park, Won Hyeok Choe, So Young Kwon, Byung-Chul Yoo
The Korean Journal of Internal Medicine.2021; 36(2): 292. CrossRef Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy
Chung-Feng Huang, Ming-Lung Yu
Clinical and Molecular Hepatology.2020; 26(3): 251. CrossRef Eradication of Hepatitis C Virus (HCV) Improves Survival of Hepatocellular Carcinoma Patients with Active HCV Infection – A Real-World Cohort Study Yang Luo, Yue Zhang, Di Wang, Di Shen, Yi-Qun Che
Cancer Management and Research.2020; Volume 12: 5323. CrossRef Hepatocellular Carcinoma Risk According to Regimens for Eradication of Hepatitis C Virus; Interferon or Direct Acting Antivirals
Hye Won Lee, Dai Hoon Han, Hye Jung Shin, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
Cancers.2020; 12(11): 3414. CrossRef
|